Latest Depression News

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Infinity Lithium secures a three-month extension for its San José lithium project amid regulatory challenges, while reshuffling its board to pivot towards Australian precious metals.

MC Mining reports zero lost time injuries and steady progress on its flagship Makhado Project, while Uitkomst Colliery implements a turnaround plan that boosts sales despite production challenges.

South Harz Potash Limited has bolstered its balance sheet through a combined A$2.39 million equity raise, positioning itself to pursue a dual-asset strategy targeting new critical minerals while preserving its core German potash project.

Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.

TrivarX has secured key approvals and begun recruiting for its innovative mental health screening trial in US veterans, while also launching a wearable tech pilot with a Major League Baseball academy in the Dominican Republic.

Bowen Coking Coal has appointed voluntary administrators after failing to secure fresh capital or negotiate with key creditors, reflecting mounting challenges in Queensland's coal sector. The administration aims to enable a sale or recapitalisation while maintaining operations at its Burton Mine Complex.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Emyria has inked a pivotal agreement with Avive Health to launch its first Empax clinic in Queensland, expanding its innovative mental health treatment network. This move builds on its recent Medibank partnership, advancing accessible, reimbursed care for treatment-resistant conditions.

Richmond Vanadium Technology has paused parts of its feasibility study and approval processes in response to a prolonged downturn in vanadium prices, focusing instead on metallurgical innovation and cash conservation.